BERLIN and BURLINGTON, Mass., Sept. 30 /PRNewswire/ —
caprotec bioanalytics GmbH announced today the commercial launch of
three new caproKits™, enabling the discovery, identification
and characterization of proteins for applications in functional
proteomics and drug development.
The three new kits are the Dasatinib caproKit, the C2 CAMP
caproKit and the Biotin Capping Kit. Together, these new kits
increase the number of commercially available caproKits to a total
of 10.
The company’s caproKits are based on the proprietary Capture
Compound Mass Spectrometry (CCMS) technology, a novel and direct
way to investigate small molecule–protein interactions
resulting in a significant functional reduction of proteome
complexity. Capture Compounds™ enable the direct isolation
and identification of defined protein classes, including membrane
proteins, out of complex biological samples.
The new and existing caproKits target different areas of
research ranging from signal transduction to epigenetics and
proteases. The Dasatinib and C2 cAMP caproKits are the newest
additions to the company’s signal transduction product line. The
Biotin Capping Kit is used to improve analytical performance by
decreasing background noise when study samples contain a high
amount of naturally biotin-modified proteins. caproKits are
versatile reagents and can be broadly used across different species
and sources of sample material. Additional caproKits for
applications in other research areas are under development and will
be released in the coming months.
“We are pleased to now offer a broad suite of products
specifically for kinases and nucleotide binding proteins, both
being of paramount importance in signal transduction and drug
discovery research,” stated Dr. Hubert Koster, CEO of caprotec
bioanalytics. “Our new caproKits are innovative and effective
chemical proteomics tools for researchers in need of a solution for
targete
‘/>”/>
